Answers are grounded in this paper and cite their sources.
Thirty-five patients with ocular rosacea were admitted to a trial of systemic oxytetracycline, 250 mg b.d. for 6 weeks. Oxytetracycline produced a significantly higher number of remissions than the placebo, 11/35. With repeated or continuous treatment 19/35 patients achieved a sustained remission for 8 months. There were no side effects. The nonspecific signs of ocular rosacea responded well to the treatment, but no permanent change in the conjunctival or corneal vascularisation occurred.
No takes yet. Share an insight, caveat, or question.
Bartholomew et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: